date:Jul 03, 2012
ed on outcomes from those clinical studies, are at present being sold into the contract manufacturing space at low purities which hurts the industry.
More not less
Like many in the antixoidants commerciasl and academic community, GCT disputed the NDL decision to remove its ORAC database.
Here is the killer question: Has the USDA proven that ORAC value is not relevant? If not they have made a very unscientific decision. In fact GCT would counter argue the USDAs reasoning and say that there is